Compare PEP & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PEP | GILD |
|---|---|---|
| Founded | 1898 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 203.2B | 170.9B |
| IPO Year | N/A | 1992 |
| Metric | PEP | GILD |
|---|---|---|
| Price | $148.79 | $141.36 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 21 |
| Target Price | ★ $160.21 | $129.10 |
| AVG Volume (30 Days) | ★ 7.8M | 6.6M |
| Earning Date | 02-03-2026 | 02-10-2026 |
| Dividend Yield | ★ 3.90% | 2.29% |
| EPS Growth | N/A | ★ 6514.05 |
| EPS | 5.26 | ★ 6.42 |
| Revenue | ★ $92,366,000,000.00 | $29,087,000,000.00 |
| Revenue This Year | $2.72 | $3.66 |
| Revenue Next Year | $3.85 | $3.32 |
| P/E Ratio | $27.74 | ★ $21.45 |
| Revenue Growth | 0.48 | ★ 2.79 |
| 52 Week Low | $127.60 | $93.10 |
| 52 Week High | $160.15 | $138.03 |
| Indicator | PEP | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 59.75 | 75.05 |
| Support Level | $143.06 | $120.95 |
| Resistance Level | $148.01 | $124.48 |
| Average True Range (ATR) | 2.62 | 4.14 |
| MACD | 0.63 | 1.99 |
| Stochastic Oscillator | 100.00 | 97.05 |
PepsiCo is a global leader in snacks and beverages, owning well-known household brands including Pepsi, Mountain Dew, Gatorade, Lay's, Cheetos, and Doritos, among others. The company dominates the global savory snacks market and also ranks as the second-largest beverage provider in the world (behind Coca-Cola) with diversified exposure to carbonated soft drinks, or CSD, as well as water, sports, and energy drink offerings. Convenience foods account for approximately 58% of its total revenue, with beverages making up the rest. Pepsi owns the bulk of its manufacturing and distribution capacity in the US, but uses bottlers overseas for beverages. International markets made up 40% of both total sales and operating profits in 2024.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).